TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers CAMBRIDGE, Mass., March 21, 2018 -- (Healthcare Sales & Marketing Network) -- TCR2 Therapeutics ... Biopharmaceuticals, Oncology, Venture Capital TCR2 Therapeutics, T cell therapies, TRuC platform
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news